Topic: Pfizer Inc.
CHICAGO (Reuters) - Academic and industry experts said on Tuesday they have convinced U.S. regulators to ease safety restrictions imposed on clinical trials of Alzheimer's drugs, a move that could improve the chances that a drug being developed jointly by Pfizer and ...
Pfizer and Eisai say FDA approves bigger dose of Aricept drug for Alzheimer's diseaseDrugmakers Eisai Inc. and Pfizer Inc. said on Saturday that government regulators have given them permission to make a larger dose of its Alzheimer's disease drug Aricept for patients ...
Medivation loses about two-thirds of value on negative study results for Alzheimer's drug Shares of Medivation Inc. plunged Wednesday after the failure of Dimebon, an Alzheimer's drug the company is developing with Pfizer Inc. Medivation stock lost about two-thirds of its value ...
Data Suggest Pfizer's Humanized Anti-Amyloid Monoclonal Antibody was Well-Tolerated in Patients with Mild to Moderate Alzheimer's Disease. "Alzheimer's disease is a destructive illness and Pfizer is committed to lifting the burden of the disease on patients and those who care for them," ...
This morning, Johnson & Johnson (JNJ) announced a definitive agreement whereby J&J will acquire substantially all of the assets and rights to Elan's (ELN) Alzheimer's Immunotherapy Program (AIP). J&J will assume and continue these activities with Wyeth (and, in time, Pfizer) in ...
Could a 25-year-old Russian cold medicine help fix Pfizer's leaky research pipeline?. Pfizer and Medivation, an upstart 30-employee company, said this morning they are teaming up to develop and eventually sell Medivation's Dimebon, an experimental treatment for Alzheimer's and Huntington's diseases, in ...
Could a 25-year-old Russian cold medicine help fix Pfizer's leaky research pipeline?. Pfizer and Medivation, an upstart 30-employee company, said this morning they are teaming up to develop and eventually sell Medivation's Dimebon, an experimental treatment for Alzheimer's and Huntington's diseases, in ...
In a packed room before thousands of neurologists, Elan and Wyeth presented long-awaited trial results for one of their drugs for Alzheimer's disease, probably the most watched experimental medicine in the pharmaceutical industry.. As expected, the data show their medicine, bapineuzumab (b-mab ...
Big drug firms like Wyeth, Elan and Eli Lilly have spent years pursuing drugs based on the theory of what causes Alzheimer's disease. The drugs aim to remove aberrant protein clumps called amyloid plaques from the brains of Alzheimer's patients. But now ...
Pfizer to Showcase Alzheimer's Research and Pipeline at Upcoming Alzheimer's Disease Medical Meeting
Jul 14, 2008 - Pfizer, Inc announced today that it will present nine abstracts from its Alzheimer's disease (AD) research and development program, including three on the two promising investigational therapies in the early stages of development, at the 2008 Alzheimer's Association ...
Photo Gallery
-
Pfizer Settlement
FBI Assistant Director of Criminal Investigative Division Kevin Perkins, right, looks on ...AP News - -
Pfizer CEO
Jeffrey Kindler, chairman and CEO of Pfizer, speaks at a news conference ...AP News - -
Pfizer to acquire Wyeth for $68 billion dollars
epa01614571 Jeffery B. Kindler, Chairman and CEO of Pfizer (L) speaks as ...ZUMA Press Inc -
From Around the Web
Video Gallery
-
Pfizer is Recalling Birth Control Pills
Pfizer Inc. is recalling about a million packages of two ...2012-02-01 -
Pfizer Considering Acquisition of Partner Icagen, ...
Drug giant Pfizer Inc (NYSE:PFE) said in a regulatory ...2011-06-27 -
Pfizer Recalls Some Birth Control Pills
Pfizer Inc. is recalling 28 lots of birth control pills ...2012-02-01
